Monthly Prescribing Reference

NORSE Eight Trial: Intravitreal Bevacizumab Noninferior to Ranibizumab for Wet AMD

Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...
JSTOR Daily

Six and eight weeks injection frequencies of bevacizumab are non-inferior to the current four weeks injection frequency for quality of life in neovascular age-related macular ...

This is a preview. Log in through your library . Abstract Purpose Patients with neovascular age-related macular degeneration (nARMD) will not deteriorate on visual acuity and retinal thickness when ...
Medscape

FDA Adds New Warnings to Avastin

September 26, 2006 — The US Food and Drug Administration (FDA) and Genentech, Inc, have notified healthcare professionals regarding safety labeling revisions for bevacizumab injection (Avastin) that ...

Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update ...